Critical Contrast: NRx Pharmaceuticals (NASDAQ:NRXP) versus Gain Therapeutics (NASDAQ:GANX)

Gain Therapeutics (NASDAQ:GANX) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, dividends, earnings, valuation and risk.

Risk & Volatility

Gain Therapeutics has a beta of -0.03, suggesting that its share price is 103% less volatile than the S&P 500. Comparatively, NRx Pharmaceuticals has a beta of 1.97, suggesting that its share price is 97% more volatile than the S&P 500.

Profitability

This table compares Gain Therapeutics and NRx Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-341.32%	-174.09%
NRx Pharmaceuticals	N/A	N/A	-395.06%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Gain Therapeutics and NRx Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1	0	5	0	2.67
NRx Pharmaceuticals	1	1	4	0	2.50

Gain Therapeutics currently has a consensus price target of $8.00, indicating a potential upside of 321.05%. NRx Pharmaceuticals has a consensus price target of $38.00, indicating a potential upside of 1,965.22%. Given NRx Pharmaceuticals’ higher possible upside, analysts plainly believe NRx Pharmaceuticals is more favorable than Gain Therapeutics.

Earnings & Valuation

This table compares Gain Therapeutics and NRx Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50,000.00	1,461.48	-$20.41 million	($0.61)	-3.11
NRx Pharmaceuticals	N/A	N/A	-$25.13 million	($2.35)	-0.78

Gain Therapeutics has higher revenue and earnings than NRx Pharmaceuticals. Gain Therapeutics is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

12.0% of Gain Therapeutics shares are owned by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are owned by institutional investors. 7.2% of Gain Therapeutics shares are owned by insiders. Comparatively, 6.4% of NRx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Gain Therapeutics beats NRx Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

About Gain Therapeutics

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.